---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-015700"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:17:49.623070+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M

## Summary
- $8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.
- Refinances ~$1.7M existing debt; net proceeds ~$5.7M after discount, fees, and debt repayment.
- Proceeds to accelerate Teverelix (GnRH Antagonist) for AURr and high CV risk prostate cancer (~$6B market).
- Optional redemption at any time at face value plus interest; Yorkville may force redemption from equity financings (excluding SEPA).

## SEC filing metadata
- accession: 0001062993-25-015700
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/0001062993-25-015700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-015700
- JSON: https://secwatch.observer/filing/0001062993-25-015700.json
- Plain text: https://secwatch.observer/filing/0001062993-25-015700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.